Floatz logo

METOCLOPRAMIDE

Granulosa Cell Ovarian Cancer

National Cancer Institute (NCI)Small moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Granulosa Cell Ovarian Cancer cohort.

Asset / SponsorPhaseRating
Arimidex
Memorial Sloan Kettering Cancer Center
Phase 2B
CIS-DIAMMINEDICHLOROPLATINUM II
GOG Foundation
Phase 2CCC
Carboplatin
GOG Foundation
Phase 2CCC
ETOPOSIDE
GOG Foundation
Phase 2CCC
BLEOMYCIN
GOG Foundation
Phase 2CCC

View all 14 →

Same molecule, other indications

METOCLOPRAMIDE is also rated in:

migraine disorderDormant
BB
Indicative ·
71 / 100
View asset →
migraine without auraDormant
BB
Indicative ·
69 / 100
View asset →
stroke disorderDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →